文献速递消化道肿瘤与早癌肝病

肝细胞癌mRECIST标准:十年应用表现与新型细化

mRECIST for HCC: Performance and novel refinements.
PubMed 文献 · J Hepatol · 2020-01-01

本文回顾了mRECIST标准自2010年提出以来在肝细胞癌中的应用表现,该标准旨在克服RECIST在局部和全身治疗肿瘤缩小评估中的局限,并细化进展评估以避免慢性肝病自然进展事件的误判。mRECIST已被欧美亚临床实践指南采纳,在早/中期HCC中成为放射学终点测量的标准工具,在晚期指南推荐mRECIST与RECIST并用。mRECIST在分子治疗中可捕捉更高的客观缓解率且与更好生存独立相关,随着免疫治疗和联合治疗的出现,需进一步细化和澄清mRECIST应用中的概念。

要点

  • mRECIST已被欧美亚HCC管理指南采纳,早/中期HCC放射学终点测量以其为标准。
  • mRECIST在分子治疗中可捕捉更高客观缓解率,且缓解与更好生存独立相关。
  • 晚期HCC指南推荐mRECIST与RECIST两种方法并用,免疫治疗时代需进一步细化概念。

核心结论

  • mRECIST已成为早/中期HCC放射学终点测量的标准工具,在晚期指南推荐与RECIST并用。
  • mRECIST在分子治疗中可捕捉更高客观缓解率,且这些缓解与更好生存独立相关。

研究设计与样本

  • 本文为综述,回顾mRECIST标准过去十年的应用表现,并结合新挑战提出澄清与细化。

主要发现

  • mRECIST已被欧洲、美国及亚洲HCC管理临床实践指南采纳或纳入。
  • mRECIST在多项II期和III期研究中用于评估缓解和事件发生时间终点。
  • mRECIST在分子治疗肿瘤中可捕捉更高客观缓解率,且缓解与更好生存独立相关。

关键数值与推荐

  • 2010年提出mRECIST标准,旨在将RECIST标准适配于HCC的特殊性。
  • 晚期HCC指南推荐mRECIST与RECIST两种方法并用。

临床怎么用

  • 早/中期HCC的放射学终点测量应采用mRECIST作为标准工具。
  • 晚期HCC评估可同时采用mRECIST与RECIST,分子治疗中mRECIST可捕捉更高客观缓解率。

局限性

  • 随着免疫治疗和联合治疗的出现,mRECIST应用中的部分概念需进一步细化和澄清。
  • 晚期HCC标准治疗变化使无进展生存期成为潜在主要终点,但需严格推荐规范。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2010, modified RECIST (mRECIST) criteria were proposed as a way of adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We intended to overcome some limitations of RECIST in measuring tumour shrinkage with local and systemic therapies, and also to refine the assessment of progression that could be misinterpreted with conventional RECIST 1.1, due to clinical events related to the natural progression of chronic liver disease (development of ascites, enlargement of lymph nodes, etc.). mRECIST has served its purpose since being adopted or included in clinical practice guidelines (European, American and Asian) for the management of HCC; it has also been instrumental for assessing response and time-to-event endpoints in several phase II and III investigations. Nowadays, mRECIST has become the standard tool for measurement of radiological endpoints at early/intermediate stages of HCC. At advanced stages, guidelines recommend both methods. mRECIST has been proven to capture higher objective response rates in tumours treated with molecular therapies and those responses have shown to be independently associated with better survival. With the advent of novel treatment approaches (i.e. immunotherapy) and combination therapies there is a need to further refine and clarify some concepts around the performance of mRECIST. Similarly, changes in the landscape of standard of care at advanced stages of the disease are pointing towards progression-free survival as a potential primary endpoint in some phase III investigations, as effective therapies applied beyond progression might mask overall survival results. Strict recommendations for adopting this endpoint have been reported. Overall, we review the performance of mRECIST during the last decade, incorporating novel clarifications and refinements in light of emerging challenges in the study and management of HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020. PMID: 31954493. doi:10.1016/j.jhep.2019.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。